Medpage Today on MSN
Regulatory T-Cell Drug Promising for Eczema, With Hint for Asthma as Well
For the primary endpoint, Eczema Area and Severity Index (EASI) improved by 53-61% in a dose-dependent manner across the ...
Everyday Health on MSN
Chronic Idiopathic Urticaria Treatment: Medication, Lifestyle Changes, and More
Treatment for chronic hives lasting at least 6 weeks may include one or more types of medication, as well as certain lifestyle changes.
When you start a medication like Dupixent (dupilumab), you expect relief from eczema or asthma, not the devastation of a cancer diagnosis. Yet ...
Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory conditions. For many, it has provided relief when other therapies failed. However, ...
Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years ...
Now, the Torquay mum of two is calling for changes to the Pharmaceutical Benefits Scheme in hopes of giving younger eczema sufferers affordable access to medications sooner. Rachel Allan, 37, said her ...
This is an active lawsuit, and none of the allegations against the defendant(s) have been proven. The contents of this page reflect the allegations in the lawsuits. Cutaneous T-cell lymphoma (CTCL) is ...
Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions ...
Delgocitinib has emerged as a promising treatment for CHE, addressing unmet needs and enhancing understanding of this complex condition, notes Raj Chovatiya, MD, PhD, MSCI.
Sanofi (NASDAQ:SNY) shares traded slightly higher in Paris on Friday after the French drugmaker reported better-than-expected Q3 2025 financial results, thanks mainly to its asthma drug Dupixent, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results